中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (9): 678-682.doi: 10.12144/zgmfskin202409678

• 综述 • 上一篇    

托法替布在皮肤科的应用进展

于芳洲1,2,杨宝琦1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2024-09-15 发布日期:2024-08-14

Update of tofacitinib in dermatology

YU Fangzhou1,2, YANG Baoqi1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-09-15 Published:2024-08-14

PDF (PC)

82

摘要： 托法替布是一种常用的JAK抑制剂，目前我国批准其用于中重度类风湿性关节炎和强直性脊柱炎，治疗皮肤病尚处于超说明书使用范畴。但越来越多的研究表明该药对银屑病、斑秃、白癜风、自身免疫性大疱病等多种皮肤病具有治疗作用。本文对托法替布在皮肤病中的作用机制、疗效及安全性进行综述，为临床治疗提供参考。

关键词: 托法替布, JAK抑制剂, 治疗

Abstract: Tofacitinib is a commonly used JAK inhibitor, which is approved in China for the treatment of moderate to severe rheumatoid arthritis and ankylosing spondylitis. Although the use of tofacitinib in dermatology is still off-label, an increasing number of studies have shown its therapeutic effects on various skin diseases such as psoriasis, alopecia areata, vitiligo, and autoimmune bullous diseases. The mechanism of action, efficacy and safety of tofacitinib in the treatment of skin diseases is reviewed in this paper to provide reference for clinical treatment.

Key words: tofacitinib, JAK inhibitor, treatment